Abstract
The development of peptide drugs and therapeutic proteins is limited by the poor permeability and the selectivity of the cell membrane. There is a growing effort to circumvent these problems by designing strategies to deliver full-length proteins into a large number of cells (Schwarze and Dowdy in Trends Pharmacol. Sci. 21:45, 2000, Ford et al. in Gene Ther. 8:1, 2001, Prochiantz in Curr. Opin. Cell Biol. 12:400, 2000). A series of small protein domains, termed protein transduction domains (PTDs), have been shown to cross biological membranes efficiently and independently of transporters or specific receptors and to promote the delivery of peptides and proteins into cells. TAT protein from human immunodeficiency virus (HIV-1) is able to deliver biologically active proteins in vivo and has been shown to be of considerable interest for protein therapeutics (Frankel and Pabo in Cell 55:1189, 1998, Mann and Frankel in EMBO J. 10:1733, 1991, Fawell in Proc. Natl. Acad. Sci. USA 91:664, 1994, Vives et al. in J. Biol. Chem. 272:16010, 1997, Schwarze et al. in Science 285:1569, 1999, Nagahara in Nat. Med. 4:1449, 1998). Similarly, the third α-helix of Antennapedia homeodomain (Derossi et al. in J. Biol. Chem. 269:10444, 1994, Lindgren et al. in Trends Pharmacol. Sci. 21:99, 2000, Chen in Proc. Natl. Acad. Sci USA 96:4325, 1999) and VP22 protein from herpes simplex virus (Elliott and O'Hare in Cell 88:223, 1997, Phelan et al. in Nat. Biotechnol. 16:440, 1998) promote the delivery of covalently linked peptides or proteins into cells. However, these PTD vectors display a certain number of limitations in that they all require crosslinking to the target peptide or protein. Moreover, protein transduction using PTD–TAT fusion protein systems may require denaturation of the protein before delivery to increase the accessibility of the TAT–PTD domain. This requirement introduces an additional delay between the time of delivery and intracellular activation of the protein (Schwarze and Dowdy in Trends Pharmacol. Sci. 21:45, 2000). In this report, we propose a new strategy for protein delivery based on a short amphipathic peptide carrier, Pep-1. This peptide carrier is able to efficiently deliver a variety of peptides and proteins into several cell lines in a fully biologically active form, without the need for prior chemical covalent coupling or denaturation steps. In addition, this peptide carrier presents several advantages for protein therapy, including stability in physiological buffer, lack of toxicity and lack of sensitivity to serum. Pep-1 technology should be extremely useful for targeting specific protein–protein interactions in living cells and for screening novel therapeutic proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schwarze, S.R. & Dowdy, S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21, 45–48 (2000).
Ford, K.G., Souberbielle, B.E., Darling, D. & Farzaneh, F. Protein transduction: an alternative to genetic intervention? Gene Ther. 8, 1–4 (2001).
Prochiantz, A. Messenger proteins: homeoproteins, TAT and others. Curr. Opin. Cell Biol. 12, 400–406 (2000).
Frankel, A.D. & Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193 (1998).
Mann, D.A. & Frankel, A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10, 1733–1739 (1991).
Fawell, S. et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664–668 (1994).
Vives, E., Brodin, P. & Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010–16017 (1997).
Schwarze, S.R., Ho, A., Vocero-Akbani, A. & Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572 (1999).
Nagahara, H. et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4, 1449–1452 (1998).
Derossi, D., Joliot, A.H., Chassaings, G. & Prochiantz, A. The third helix of the antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10444–10450 (1994).
Lindgren, M., Hällbrink, M., Prochiantz, A. & Langel, U. Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99–103 (2000).
Chen, Y.N. et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci USA 96, 4325–4329 (1999).
Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a Herpesvirus structural protein. Cell 88, 223–233 (1997).
Phelan, A., Elliott, G. & O'Hare, P. Intercellular delivery of functional p53 by the herpes virus protein VP22. Nat. Biotechnol. 16, 440–443 (1998).
Morris, M.C., Vidal, P., Chaloin, L., Heitz, F. & Divita, G. A new peptide vector for efficient delivery of oligonucleotide into nontransformed mammalian cells. Nucleic Acids Res. 25, 2730–2736 (1997).
Morris, M.C., Heitz, A., Mery, J., Heitz, F. & Divita, G. An essential phosphorylation-site domain of human cdc25C interacts with both 14-3-3 and cyclins. J. Biol. Chem. 275, 28849–28857 (2000).
Morris, M.C. et al. A new potent HIV-reverse transcriptase inhibitor: a synthetic peptide derived from interface subunit domains. J. Biol. Chem. 274, 24941–24946 (1999).
Luo, D. & Saltzman, M. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33–37 (2000).
Morris, M.C., Chaloin, L., Heitz, F. & Divita, G. Translocating peptides and proteins and their use for gene delivery. Curr. Opin. Biotechnol. 11, 461–466 (2000).
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983).
Acknowledgements
This work was supported in part by the Centre National de la Recherche Scientifique (CNRS) and by grants from the Association pour la Recherche sur le Cancer (ARC-5271) and the Agence Nationale de Recherche sur le Sida (ANRS). The Pep-1/Chariot project was supported by Active Motif (Carlsbad, CA). We thank K. Hondorp, J. Archdeacon and L. Chaloin for constructive discussions and advice. We also thank M. Dorée for continuous support and P. Travo, head of IFR 24 Integrated Imaging Facility, for technical advice on microscopy.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morris, M., Depollier, J., Mery, J. et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19, 1173–1176 (2001). https://doi.org/10.1038/nbt1201-1173
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1201-1173
This article is cited by
-
Fabrication, characterization and evaluation of a new designed botulinum toxin-cell penetrating peptide nanoparticulate complex
DARU Journal of Pharmaceutical Sciences (2023)
-
Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
Molecular Biotechnology (2023)
-
TAQing2.0 for genome reorganization of asexual industrial yeasts by direct protein transfection
Communications Biology (2022)
-
Characterization and Evaluation of Cell-Penetrating Activity of Brevinin-2R: An Amphibian Skin Antimicrobial Peptide
Molecular Biotechnology (2022)
-
Prospect of cell penetrating peptides in stem cell tracking
Stem Cell Research & Therapy (2021)